title: Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.
abstract: Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load <6,000,000 IU/mL. The effectiveness of this regimen, however, has not been fully confirmed by real-world experience. Using data from real-world cohorts, we aimed to determine the effectiveness of 8 weeks of LDV/SOF treatment, examine variables associated with relapse after treatment with this regimen, and compare the effectiveness of 8 weeks and 12 weeks of LDV/SOF treatment. To evaluate the effectiveness of 8 weeks of therapy and characteristics associated with relapse, we used individual patient data from the IFI (Institut für Interdisziplinäre Medizin), Burman's Pharmacy, and Kaiser Permanente Southern California. All patients had fibrosis staging assessed with biopsy, transient elastography, or serum biomarkers. We also performed a systematic review and meta-analysis of six additional real-world cohorts, to compare effectiveness of 8 weeks to 12 weeks duration. In our pooled data analysis, 634 patients were treated for 8 weeks with LDV/SOF, of whom all had outcomes of cure or relapse without loss to follow-up. Per protocol rates of sustained virologic response at 12 weeks were 98.1% (622/634) in the full cohort and 97.9% (571/583) among treatment-eligible patients. Exact logistic regression revealed no specific patient characteristics associated with relapse. Our meta-analysis of six additional real-world cohorts, comprised of 5,637 patients, demonstrated similar risk for relapse between 8 weeks and 12 weeks of LDV/SOF (relative risk = 0.99, 95% confidence interval 0.98-1.00).
  
  
  
  An 8-week duration of treatment with LDV/SOF is highly effective in properly selected patients; greater use of this regimen is recommended. (Hepatology 2017;65:1094-1103).
authors.affiliation: Liver Care Network, Swedish Medical Center, Seattle, WA.
authors.forename: Kris V
authors.initials: KV
authors.lastname: Kowdley
authors.affiliation: Department of Medicine and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
authors.forename: Vinay
authors.initials: V
authors.lastname: Sundaram
authors.affiliation: Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA.
authors.forename: Christie Y
authors.initials: CY
authors.lastname: Jeon
authors.affiliation: Department of Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA.
authors.forename: Kamran
authors.initials: K
authors.lastname: Qureshi
authors.affiliation: Department of Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA.
authors.forename: Nyan L
authors.initials: NL
authors.lastname: Latt
authors.affiliation: Department of Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA.
authors.forename: Amandeep
authors.initials: A
authors.lastname: Sahota
authors.affiliation: Burmans-Diplomat Specialty Pharmacy, Flint, MI.
authors.forename: Stephen
authors.initials: S
authors.lastname: Lott
authors.affiliation: Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA.
authors.forename: Michael P
authors.initials: MP
authors.lastname: Curry
authors.affiliation: Department of Medicine, University of Hawaii, Honolulu, HI.
authors.forename: Naoky
authors.initials: N
authors.lastname: Tsai
authors.affiliation: School of Pharmacy, Monash University Malaysia, Malaysia.|Centre of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.|School of Population Health, University of Queensland, Brisbane, Australia.|School of Pharmacy, University of Wisconsin-Madison, Madison, WI.
authors.forename: Nathorn
authors.initials: N
authors.lastname: Chaiyakunapruk
authors.affiliation: TRIO Health Analytics, La Jolla, CA.
authors.forename: Yoori
authors.initials: Y
authors.lastname: Lee
authors.affiliation: IFI Institut für Interdisziplinäre Medizin, Asklepios Klinik St. Georg, Hamburg, Germany.
authors.forename: Jorg
authors.initials: J
authors.lastname: Petersen
authors.affiliation: IFI Institut für Interdisziplinäre Medizin, Asklepios Klinik St. Georg, Hamburg, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Buggisch
mesh_terms: D000328:Adult; D001562:Benzimidazoles / Q000627:therapeutic use*; D001707:Biopsy, Needle; D015331:Cohort Studies; D016001:Confidence Intervals; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005449:Fluorenes / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011237:Predictive Value of Tests; D012008:Recurrence; D018570:Risk Assessment; D012720:Severity of Illness Index; D000069474:Sofosbuvir / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001562:Benzimidazoles; D005449:Fluorenes; C586541:ledipasvir; D000069474:Sofosbuvir